NASDAQ:MIST Milestone Pharmaceuticals (MIST) Stock Price, News & Analysis → The ONE AI sSock to own now. (It’s not Nvidia.) (From Weiss Ratings) (Ad) Free MIST Stock Alerts $1.49 +0.04 (+2.76%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$1.39▼$1.5250-Day Range$1.40▼$2.2052-Week Range$1.33▼$4.49Volume291,545 shsAverage Volume639,498 shsMarket Capitalization$49.89 millionP/E RatioN/ADividend YieldN/APrice Target$11.20 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Milestone Pharmaceuticals alerts: Email Address Milestone Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside651.7% Upside$11.20 Price TargetShort InterestHealthy1.35% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.37) to ($1.02) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.00 out of 5 starsMedical Sector379th out of 946 stocksPharmaceutical Preparations Industry179th out of 437 stocks 3.4 Analyst's Opinion Consensus RatingMilestone Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.20, Milestone Pharmaceuticals has a forecasted upside of 651.7% from its current price of $1.49.Amount of Analyst CoverageMilestone Pharmaceuticals has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.35% of the outstanding shares of Milestone Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverMilestone Pharmaceuticals has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Milestone Pharmaceuticals has recently increased by 19.80%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMilestone Pharmaceuticals does not currently pay a dividend.Dividend GrowthMilestone Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MIST. Previous Next 2.5 News and Social Media Coverage News SentimentMilestone Pharmaceuticals has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Milestone Pharmaceuticals this week, compared to 1 article on an average week.Search Interest5 people have searched for MIST on MarketBeat in the last 30 days. MarketBeat Follows5 people have added Milestone Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Milestone Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders10.40% of the stock of Milestone Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.32% of the stock of Milestone Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Milestone Pharmaceuticals are expected to grow in the coming year, from ($1.37) to ($1.02) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Milestone Pharmaceuticals is -1.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Milestone Pharmaceuticals is -1.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMilestone Pharmaceuticals has a P/B Ratio of 0.77. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceThey said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.There are five coins you must take a look at right away. About Milestone Pharmaceuticals Stock (NASDAQ:MIST)Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. Milestone Pharmaceuticals Inc. has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.Read More MIST Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MIST Stock News HeadlinesFebruary 29, 2024 | globenewswire.comMilestone® Pharmaceuticals to Participate in a Corporate Panel Discussion at TD Cowen 44th Annual Health Care ConferenceFebruary 29, 2024 | globenewswire.comMilestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded WarrantsMarch 19, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.February 28, 2024 | marketwatch.comMilestone Pharma Shares Drop After Public Offering NewsFebruary 28, 2024 | msn.comMilestone Pharmaceuticals launches stock and warrants offeringFebruary 28, 2024 | globenewswire.comMilestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded WarrantsFebruary 26, 2024 | markets.businessinsider.comMilestone Pharmaceuticals Earns Buy Rating on Strong Regulatory and Financial OutlookFebruary 26, 2024 | msn.comWhy Milestone Pharmaceuticals (MIST) Stock Is RisingMarch 19, 2024 | Prosper Trading Academy (Ad)Did you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:February 26, 2024 | finance.yahoo.comMilestone Pharmaceuticals Announces Plan to Resubmit NDA for Etripamil for the Treatment of PSVTFebruary 21, 2024 | benzinga.comMilestone Pharmaceuticals Stock (NASDAQ:MIST) Insider TradesFebruary 13, 2024 | marketwatch.comMerrimack Pharmaceuticals to Get $225M Milestone Payment After FDA's Supplemental NDA ApprovalFebruary 11, 2024 | finance.yahoo.comMilestone Pharmaceuticals Inc. (MIST)January 31, 2024 | reuters.comNovartis eyes 5% annual sales growth through 2028January 25, 2024 | businesswire.comDr. Ferrer BioPharma Awarded Winner at CPHI Pharmapack 2024 for Groundbreaking GentleMist TechnologyJanuary 20, 2024 | stockhouse.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Milestone Pharmaceuticals Inc.- MISTJanuary 16, 2024 | finance.yahoo.comDown -43.64% in 4 Weeks, Here's Why Milestone Pharmaceuticals (MIST) Looks Ripe for a TurnaroundDecember 30, 2023 | markets.businessinsider.comROSEN, A LONGSTANDING LAW FIRM, Encourages Milestone Pharmaceuticals Inc. Investors to Inquire About Securities Class Action Investigation - MISTDecember 28, 2023 | benzinga.comMilestone Pharmaceuticals Stock (NASDAQ:MIST), Analyst Ratings, Price Targets, PredictionsDecember 28, 2023 | benzinga.comMilestone Pharmaceuticals Stock (NASDAQ:MIST) Dividends: History, Yield and DatesDecember 27, 2023 | markets.businessinsider.comMilestone Pharmaceuticals Earns Buy Rating Amid Promising Clinical Trials and Market PotentialDecember 27, 2023 | finance.yahoo.comMilestone Pharma (MIST) Down on Regulatory Update for EtripamilDecember 26, 2023 | businesswire.comROSEN, A LEADING LAW FIRM, Encourages Milestone Pharmaceuticals Inc. Investors to Inquire About Securities Class Action Investigation – MISTDecember 26, 2023 | markets.businessinsider.comMilestone Pharma Receives Refusal To File Letter From FDA For NDA For Etripamil In PSVT TreatmentDecember 26, 2023 | msn.comWhy Is Heart Disease-Focused Milestone Pharmaceuticals Stock Plummeting Today?December 26, 2023 | finance.yahoo.comMilestone Pharmaceuticals Inc.'s (NASDAQ:MIST) top owners are individual investors with 52% stake, while 34% is held by institutionsDecember 26, 2023 | finance.yahoo.comMilestone Pharmaceuticals Receives Refusal to File Letter from U.S. FDA for New Drug Application for Etripamil in the Treatment of PSVTSee More Headlines Receive MIST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Milestone Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/12/2021Today3/18/2024Next Earnings (Estimated)4/03/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MIST CUSIPN/A CIK1408443 Webwww.milestonepharma.com Phone(514) 336-0444FaxN/AEmployees39Year FoundedN/APrice Target and Rating Average Stock Price Target$11.20 High Stock Price Target$25.00 Low Stock Price Target$4.00 Potential Upside/Downside+651.7%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-58,390,000.00 Net MarginsN/A Pretax Margin-1,316.69% Return on Equity-125.27% Return on Assets-64.11% Debt Debt-to-Equity Ratio1.72 Current Ratio10.45 Quick Ratio10.45 Sales & Book Value Annual Sales$5 million Price / Sales9.98 Cash FlowN/A Price / Cash FlowN/A Book Value$1.94 per share Price / Book0.77Miscellaneous Outstanding Shares33,480,000Free Float30,001,000Market Cap$49.89 million OptionableOptionable Beta1.77 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Joseph G. Oliveto M.B.A. (Age 56)CEO, President & Director Comp: $905.71kMr. Amit Hasija (Age 51)CFO & Executive VP of Corporate Development Comp: $603.18kDr. David B. Bharucha FACC (Age 62)M.D., Ph.D., Chief Medical Officer Comp: $440.67kDr. Philippe Douville M.B.A. (Age 62)Ph.D., Founder, Strategic Advisor & Member of Scientific Advisory Board Mr. Jeff Nelson (Age 43)Chief Operating Officer Ms. Kim FoxVice President of CommunicationsDr. Philip T. Sager FACC (Age 68)FAHA, FHRS, M.D., Chief Medical Advisor & Member of the Scientific Advisory Board Dr. Guy RousseauSVP of Regulatory Affairs and Quality ManagementMs. Anita HolzVP & Head of Medical AffairsMore ExecutivesKey CompetitorsUnicycive TherapeuticsNASDAQ:UNCYTiziana Life SciencesNASDAQ:TLSACara TherapeuticsNASDAQ:CARABolt BiotherapeuticsNASDAQ:BOLTRegulus TherapeuticsNASDAQ:RGLSView All CompetitorsInstitutional OwnershipGoldman Sachs Group Inc.Sold 1,205,657 shares on 3/1/2024Ownership: 4.041%Virtu Financial LLCBought 18,686 shares on 2/26/2024Ownership: 0.056%Barclays PLCSold 390,305 shares on 2/15/2024Ownership: 0.762%Goldman Sachs Group Inc.Sold 1,205,657 shares on 2/13/2024Ownership: 4.041%Northern Trust CorpBought 31,970 shares on 2/13/2024Ownership: 0.095%View All Institutional Transactions MIST Stock Analysis - Frequently Asked Questions Should I buy or sell Milestone Pharmaceuticals stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Milestone Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MIST shares. View MIST analyst ratings or view top-rated stocks. What is Milestone Pharmaceuticals' stock price target for 2024? 5 brokerages have issued 12-month price objectives for Milestone Pharmaceuticals' stock. Their MIST share price targets range from $4.00 to $25.00. On average, they predict the company's share price to reach $11.20 in the next year. This suggests a possible upside of 651.7% from the stock's current price. View analysts price targets for MIST or view top-rated stocks among Wall Street analysts. How have MIST shares performed in 2024? Milestone Pharmaceuticals' stock was trading at $1.67 on January 1st, 2024. Since then, MIST stock has decreased by 10.8% and is now trading at $1.49. View the best growth stocks for 2024 here. Are investors shorting Milestone Pharmaceuticals? Milestone Pharmaceuticals saw a increase in short interest in February. As of February 29th, there was short interest totaling 451,300 shares, an increase of 19.8% from the February 14th total of 376,700 shares. Based on an average trading volume of 410,100 shares, the days-to-cover ratio is currently 1.1 days. View Milestone Pharmaceuticals' Short Interest. When is Milestone Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 3rd 2024. View our MIST earnings forecast. How were Milestone Pharmaceuticals' earnings last quarter? Milestone Pharmaceuticals Inc. (NASDAQ:MIST) issued its quarterly earnings results on Friday, November, 12th. The company reported ($0.34) EPS for the quarter, beating analysts' consensus estimates of ($0.38) by $0.04. What other stocks do shareholders of Milestone Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Milestone Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), CymaBay Therapeutics (CBAY), iBio (IBIO), Allena Pharmaceuticals (ALNA), Fulcrum Therapeutics (FULC), OPKO Health (OPK), VYNE Therapeutics (VYNE), Soleno Therapeutics (SLNO) and Agile Therapeutics (AGRX). When did Milestone Pharmaceuticals IPO? (MIST) raised $75 million in an initial public offering on Thursday, May 9th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, Cowen and Piper Jaffray acted as the underwriters for the IPO and Oppenheimer & Co. was co-manager. Who are Milestone Pharmaceuticals' major shareholders? Milestone Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Goldman Sachs Group Inc. (4.04%), Goldman Sachs Group Inc. (4.04%), BML Capital Management LLC (1.32%), Barclays PLC (0.76%), Dimensional Fund Advisors LP (0.22%) and Northern Trust Corp (0.10%). Insiders that own company stock include David Bharucha, Debra K Liebert, Paul F Truex, Robert James Wills and Rtw Investments, Lp. View institutional ownership trends. How do I buy shares of Milestone Pharmaceuticals? Shares of MIST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MIST) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThe world’s greatest investmentPorter & CompanySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders Agency Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Milestone Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.